Microfluidic EPG Array for High-Throughput Nematode Screening

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for anthelmintic drug discovery are slow and ineffective in addressing nematode infections, particularly due to the emergence of resistant strains, necessitating rapid and inexpensive screening methods for candidate drugs.

Innovation Solution

Development of devices and systems for measuring electropharyngeograms (EPGs) in nematodes, including microfluidic devices that allow for the sorting, immobilization, and optical imaging of organisms, enabling the identification of therapeutic or toxic compounds, including anthelmintic activity screening.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional anthelmintic drug discovery methods are used, then drug development can proceed through traditional pathways, but the process is slow and ineffective against resistant strains

Engineering Contradiction:
Improvedrug discovery speedVSAvoideffectiveness against resistant strains
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent segments the drug discovery process by implementing high-throughput screening that simultaneously tests multiple compounds against multiple nematode strains in parallel. The array-based system divides the screening into independent channels, each capable of autonomous measurement, thereby accelerating productivity while maintaining reliability through diverse strain testing

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent changes the measurement parameters by using electropharyngeogram (EPG) recording to directly assess pharyngeal pumping activity as a readout for anthelmintic efficacy. This physiological parameter measurement provides real-time, quantitative data on drug effectiveness against both susceptible and resistant strains, enabling faster and more reliable screening

Inventive Principle:
Principle #35Parameter changes

2Productivity

If high-throughput screening is implemented to improve drug discovery speed, then productivity increases, but device complexity and cost may increase

Engineering Contradiction:
Improvescreening throughputVSAvoidmicrofluidic array complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The microfluidic array is designed with self-service features where fluidic pressure automatically sorts and positions nematodes into recording chambers without manual intervention. The system uses passive mechanical sorting based on nematode size and shape, eliminating the need for complex automated manipulation mechanisms while maintaining high throughput

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent implements multi-functionality by designing a single microfluidic array that can simultaneously perform sorting, immobilization, EPG recording, and optical imaging across multiple channels. This universal platform handles diverse nematode strains and multiple test compounds in parallel, achieving high productivity without proportionally increasing device complexity

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Productivity

If multiple organisms are screened simultaneously to improve productivity, then screening efficiency increases, but measurement precision and data quality may be compromised

Engineering Contradiction:
Improvesimultaneous screening capacityVSAvoidEPG recording accuracy
Core Design Contradiction:
ProductivityVSMeasurement precision

Solution Approach 1:

The patent segments the measurement process by providing dedicated EPG recording electrodes and isolation chambers for each nematode in the array. Each channel operates as an independent measurement unit with its own signal acquisition pathway, ensuring that simultaneous screening of multiple organisms does not compromise the precision of individual EPG recordings

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses an intermediary isolation medium in the microfluidic channels that maintains appropriate electrical properties for EPG recording while allowing simultaneous measurement across multiple channels. The fluidic isolation between channels prevents electrical interference, preserving measurement precision during high-throughput simultaneous screening

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables rapid and cost-effective high-throughput screening for anthelmintic compounds by simultaneously measuring EPGs from multiple organisms, effectively addressing the challenge of resistant nematode strains and improving drug discovery efficiency.

Implementation Method 1

Each recording module is connected to an electrode channel... One waste reservoir is connected to the electrode channel

Methodology Applied
Scientific EffectFluid flow:

Implementation Method 2

measuring an electropharyngeogram (EPG)... Each recording module is also connected to a pair of waste reservoirs

Methodology Applied
Scientific EffectElectrical signal detection:

Data Source

PatentUS9723817B2Electropharyngeogram arrays and methods of use
Publication Date: 2017.08.08 UNIVERSITY OF OREGON
  • US9723817B2 patent drawing
  • US9723817B2 patent drawing
  • US9723817B2 patent drawing

AI summary

Disclosed herein are devices, systems, and methods for measuring an electropharyngeogram (EPG) in living organisms. In some embodiments, the devices and systems disclosed herein include an array for sorting and immobilizing an organism (such as a nematode) for measurement of an EPG and/or optical imaging. Also disclosed are methods for identifying therapeutic or toxic compounds utilizing the disclosed devices and systems. In some embodiments, the methods include screening for compounds with anthelmintic activity, toxicity (for example HERG channel blockers), or candidate drugs for treatment of a variety of human and/or animal diseases.